News

June 2, 2025

Tagworks to present at the Antibody Engineering & Therapeutics Meeting in Basel 2025

Tagworks will present how its Click-to-Release platform affords in vivo control over drug activity to address the limited therapeutic window and application scope of several targeted cancer therapies, applied to ADCs (i.e. TGW101, Tagworks’ lead clinical program) as well as targeted radiotherapies. The Antibody Engineering & Therapeutics Europe Conference will …
May 23, 2025

Tagworks Highlighted in Nature Biotechnology

We’re proud to share that Nature Biotechnology has published a new article featuring an interview with our CEO, Marc Robillard. The article includes a dedicated section on Tagworks, beginning on page three and continuing into page four. We invite you to read the full article via this link.
May 16, 2025

Tagworks to present at the J&J R&D Symposium on Antibody Conjugates

On June 19th, 2025, Marc Robillard will give a presentation about Tagworks’ Click-to-Release platform for ADCs and targeted radiotherapies at the Johnson & Johnson R&D Symposium on Antibody Conjugates in Beerse, Belgium. At this symposium exciting advancements in discovery and development of antibody-drug conjugates and targeted radiotherapies are explored by …
April 22, 2025

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer 

Tagworks initiates Phase 1 trial for TGW101, a first-in-class Click-to-Release ADC targeting TAG-72, and appoints Dr. Keith Orford as Chief Medical Officer.
March 25, 2025

Tagworks Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

Tagworks to present preclinical data demonstrating potential of its Click-to-Release platform to enable safe, tolerable, and potent delivery of therapeutic candidates for solid tumors
October 1, 2024

Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025
October 1, 2024

Tagworks to present click-cleavable radiotherapeutics program at TRP Summit

Marc Robillard will present the progress of Tagworks click-cleavable radiotherapeutics program at the 6th Targeted Radiopharmaceuticals Summit in Amsterdam on December 5, 2024.
September 9, 2024

Tagworks appoints Krisztina Nemenyi as Vice President Regulatory Affairs

We are excited to announce a recent addition to our rapidly expanding team: Krisztina Nemenyi has joined as our Vice President Regulatory Affairs.
July 6, 2024

Tagworks will present at The Antibody Series 2024

Madeira, September 4-6, 2024; www.antibodyseries.com
July 6, 2024

Tagworks will present at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit 2024

Boston, September 9-10, 2024; www.adc-partnering.com

Curious about what we do? Get in touch!

Logo-2

About    Our Technology   Pipeline    Join us    News    Contact

Contact
T +31 85 800 8550
info@tagworkspharma.com

Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2025 | Terms of use | Privacy StatementDesign by Ape to Zebra